The Impact Of ADAPTABLE: The Industry's First And Largest Fully Decentralized Clinical Megatrial

For over half a century, millions of Americans living with heart disease have relied on a daily dose of aspirin to help prevent a heart attack or stroke. The most commonly prescribed dosages are 81 mg and 325 mg. The goal of the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) study is to determine the dosage that most effectively maximizes results while minimizing harmful side effects such as internal bleeding. The study is led by researchers at the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization and a part of the Duke School of Medicine.

The ADAPTABLE study team has compiled multiple partners and platforms to support the study. One partner is Mytrus and its Engage service, an electronic virtual trial platform based on high-profile work with other global pharmaceutical and biopharmaceutical companies. When Mytrus was acquired by Medidata in 2017, Engage became the core technology behind Rave Virtual Trials, an intuitive, web-based application that serves as the patient-facing interface for 100 percent virtual trials and hybrid studies. Rave Virtual Trials provided the platform needed to remotely manage the informed consent process, enrollment, and randomization of ADAPTABLE participants while allowing them to easily report their health outcomes throughout the study from the comfort of their homes.